Læknablaðið - 15.06.1996, Side 23

LÆKNABLAÐIÐ 1996; 82
449
4. Prisant LM, Weir MR, Papademetriou V, Weber MA,
Adegbile IA, Alemayehu D, et al. Low- dose drug com-
bination therapy: an alternative first-line approach to
hypertension treatment. Am Heart J 1995; 130: 359-66.
5. SwalesJD. Pharmacological treatment of hypertension.
Lancet 1994; 344: 380-4.
6. Whelton PK. Epidemiology of hypertension. Lancet
1994; 344: 101-6.
7. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P,
Neaton J, et al. Blood pressure, stroke, and coronary
heart disease. Part 1, prolonged differences in blood
pressure: prospective observational studies corrected
for the regression dilution bias. Lancet 1990; 335: 765-
74.
8. The fifth report of the Joint National Committee on
detection, evaluation, and treatment of high blood pres-
sure (JNC V). Arch Intern Med 1993; 153: 154-83.
9. Sever P, Beevers G, Bulpitt C, Lever A, Ramsay L,
Reid J, et al. Management guidelines in essential hyper-
tension: report of the second working party of the Brit-
ish Hypertension Society. BMJ 1993; 306: 983-7.
10. Jackson R, Barham P, Bilts J, Birch T, McLennan L,
MacMahon S, et al. Management of raised blood pres-
sure in New Zealand: a discussion document. BMJ 1993;
307: 107-10.
11. Beto JA, Bansal VK. Quality of life in treatment of
hypertension. A metaanalysis of clinical trials. Am J
Hypert 1992; 5: 125-33.
12. Liebson PR, Grandits GA, Dianzumba S, Prineas RJ,
Grimm RH Jr, Neaton JD, et al. for the Treatment of
Hypertension Study Group. Comparison of ftve anti-
hypertensive monotherapies and placebo for change in
Ieft ventricular mass in patients receiving nutritional-
hygienic therapy in the treatment of mild hypertension
study (TOMHS). Circulation 1995; 91: 678-706.